Results 231 to 240 of about 119,037 (316)

The Dynamic Evolution of Lipid Profiles Following Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
Cirrhosis is frequently accompanied by varying degrees of lipid profile abnormalities. This study confirms that these profiles are differentially affected by disease etiology and progressively worsen—with significant reductions in TC, HDL‐C, and LDL‐C—as liver disease severity increases. TIPS improves lipid profiles, particularly by increasing HDL‐C in
Jiamin Xu, Qinnian Li, Lagan Kumar Manandhar, Bilian Zhu, Chenrui Zhang, Weimin Bao, Yingmei Tang   +6 more
wiley   +1 more source

Intestinal decontamination with rifaximin attenuates LSEC dysfunction and liver fibrosis in mice. [PDF]

PLoS One
Su T, Lai S, Chen H.
europepmc   +1 more source

Orthotopic liver transplantation [PDF]

, 1980
Starzl, TE
core  

Chinese Registry on Transjugular Intrahepatic Portosystemic Shunts (CN‐TIPS): Protocol for a Registry‐Based, Prospective Prognostic Study

Portal Hypertension &Cirrhosis, EarlyView.
CN‐TIPS is a nationwide, multicenter prospective registry that will enroll 10,000 adults with portal hypertension undergoing transjugular intrahepatic portosystemic shunt in China, integrating perioperative clinical and hemodynamic metrics with standardized imaging (including computational modeling in a dedicated subcohort) and multi‐omics biospecimens,
Yi Xiang, Yong Lv, Hongwei Zhou, Jianbo Zhao, Meng Niu, Jiacheng Liu, Guangchuan Wang, Qi Zhang, Weizhong Zhou, Beijia Yu, Jun Chi, Guo Han, Jiawei Zhang, Long Gao, Wenjing Liu, Zhang Zhang, Tianyu Liu, Wuhua Guo, He Zhao, Gao‐Jun Teng, Xiaolong Qi   +20 more
wiley   +1 more source

Evaluation of a 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet-induced mouse model in a comparative experimental study of portal hypertension. [PDF]

World J Gastroenterol
Zhao JB, Wu ZH, Lin JY, Luo GQ, Zhang CH, Wu GB, Fan Q, Qi XL, Huo HZ, Yu JW, Li HJ, Zheng L, Luo M.   +12 more
europepmc   +1 more source

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Portal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang, Zhenyu Liu, Jun Lin, Weijing Zhang, Xianzhi Liu, Tong Zhang   +5 more
wiley   +1 more source

New insights into combined immunotherapy for hepatocellular carcinoma associated with liver cirrhosis. [PDF]

Front Immunol
Liu Y, Cong K, Li Q, Zhang D, Sheng J.
europepmc   +1 more source

Establishment and Comparative Analysis of Radiation‐Induced Liver Disease in Normal and Fibrotic Rat Models

Precision Radiation Oncology, EarlyView.
This study successfully established two novel rat models of radiation‐induced liver disease (RILD), one in healthy livers and the other in TAA‐induced fibrotic livers, providing valuable insights into the combined effects of radiation and pre‐existing fibrosis.
Yanting Jiang, Yuxi Ding, Fang Wang, Danni Chen, Weixiang Zhong, Zhongjie Lu, Yixiang J. Wang, Senxiang Yan, Xiaoguang Liu, Feng Zhao   +9 more
wiley   +1 more source

Microplastics and nanoplastics: Emerging drivers of liver damage and metabolic dysfunction. [PDF]

Hepatol Forum
Yilmaz Y, Simsek C, Ucdal M, Kaya E.
europepmc   +1 more source